HeXun Biosciences Co Ltd
TTPEX:698643.80
TWD
-0.85
(-1.90%)
ISIN
TW0006986003
Return %
Stock
S&P 500
1Y
-23.83
14.20
3Y
-43.85
81.12
5Y
- -
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Cheng Han Wen
- Full Time Employees
- 53
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- No. 1490, Chunri Road Taoyuan TAO Taiwan 33022
- IPO Date
- Sep 7, 2023
- Website
- hexunbio.com
- Similar Companies
- Business
- HeXun Biosciences Co., Ltd. operates as a biotechnology company primarily engaged in the research, development, manufacture, and sale of innovative biopharmaceutical products and medical technologies. Its core products include recombinant protein drugs, monoclonal antibodies, diagnostic reagents, biopharmaceutical raw materials, and related pharmaceutical preparations. The company focuses on products serving oncology, autoimmune diseases, infectious diseases, and other critical therapeutic areas. HeXun Biosciences targets healthcare institution clients, pharmaceutical companies, and research entities primarily within China but with expanding international market interests. Founded in 2017 and headquartered in China, HeXun Biosciences has strengthened its R&D capabilities and product pipeline through strategic collaborations and capital investments in the last two years. Notably, it has entered partnerships to enhance its biologics manufacturing technologies and expand its diagnostics portfolio. The company also recently launched new biosimilar drugs and advanced diagnostic kits aimed at improving disease detection and treatment efficacy. These developments reflect its ongoing strategic emphasis on integrating cutting-edge biotechnologies with commercial-scale production to accelerate market presence and innovation leadership. HeXun Biosciences operates within the biotechnology and pharmaceutical industry segments, focusing on biopharmaceutical innovation, production, and medical diagnostics. The company serves hospitals, clinical laboratories, pharmaceutical developers, and research organizations, aiming to meet the rising demand for biologics and health technology solutions. With a growing product portfolio, recent technological advancements, and enhanced manufacturing capacity, HeXun Biosciences continues expanding its footprint in the Asia-Pacific region and beyond, underpinning its role as a key player in China's life sciences sector.